Please assess the completion status of the following clinical trial:

Trial Title: The Pharmacokinetics of Dexmedetomidine in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 3 - 11.9 years~  * 2 age groups: 3.0 - 5.9 years, 6.0 - 11.9 years~* Patients will be equally distributed within each age group~* Meets criteria to receive dexmedetomidine sedation for MRI:~  * Active, uncontrolled gastroesophageal reflux - an aspiration risk~ * Active, uncontrolled vomiting - an aspiration risk~ * Current (or within past 3 months) history of apnea requiring an apnea monitor~ * Active, current respiratory issues that are different from the baseline status (pneumonia,exacerbation of asthma, bronchiolitis, respiratory syncytial virus)~ * Unstable cardiac status (life threatening arrhythmias, abnormal cardiac anatomy,significant cardiac dysfunction)~ * Craniofacial anomaly, which could make it difficult to effectively establish a mask airway for positive pressure ventilation if needed~ * Current use of digoxin~ * Moya Moya Disease~ * New-onset stroke~ * Provide written consent to take part in the research study~Exclusion Criteria:~* Do not meet established sedation criteria~* History of allergy, intolerance, or reaction to dexmedetomidine or hypersensitivity~* Previous diagnosis of hepatic insufficiency/failure or a serum glutamate pyruvate transaminase level \> 2 times the normal limit determined by Children's Hospital Boston (TCH)~* Current diagnosis of renal insufficiency/failure or a current serum creatinine level \> 1.5 times the normal limit determined by TCH~* Have received digoxin in the past (no time limit)~* Received phenobarbital, clonidine or valproic acid within 30 days~* Current, repaired or risk of Moya-Moya disease~* Recent stroke (cerebrovascular accident) within past 6 months~* Uncontrolled hypertension~* Concomitant use of beta antagonist, or calcium channel blocker~* Participated in a clinical investigation within the past three months

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).